Colgate-Palmolive faces key board, dividend moves

Colgate-Palmolive has announced a higher shareholder payout and changes to its board as it heads toward a closely watched annual meeting in May 2026. On March 11, the company’s board approved an increase in the quarterly dividend to $0.53 per share from $0.52, effective in the second quarter of 2026.

On an annual basis, the dividend will rise to $2.12 per share from $2.08. Colgate-Palmolive has paid uninterrupted dividends on its common stock since 1895, and is included among major dividend lists such as Dividend Kings and Aristocrats.

These moves come as the stock trades at $85.49 with a value score of 2. The shares show a 23.3% return over three years and 22.1% over five years, while the one-year return is a 4.8% decline, contrasting with a 10.0% gain year to date.

Alongside the dividend increase, Colgate-Palmolive reported that Christopher Boerner, Ph.D., has been elected to its board of directors, effective March 15, 2026. Boerner serves as board chair and chief executive officer of Bristol-Myers Squibb (BMY).

Boerner has been CEO of Bristol-Myers Squibb (BMY) since November 2023 and board chair since April 2024. He previously served as executive vice president and chief operating officer in 2023 and as executive vice president and chief commercialization officer from 2018 to 2023, after leading international and U.S. commercial markets.

The company also said that Steven A. Cahillane has informed the board he will not stand for reelection at the annual meeting of stockholders on May 8, 2026. Colgate-Palmolive CEO Noel Wallace stated the company was pleased to welcome Boerner and thanked Cahillane for his service and contributions.

At the May 8, 2026 annual meeting, two shareholder proposals will put Colgate-Palmolive’s board structure and boardroom priorities under scrutiny. One proposal, submitted by governance activist John Chevedden, seeks to require that the chief executive officer and board chair roles be held by different individuals.

A second proposal from the National Legal and Policy Center asks the company to remove diversity, equity, and inclusion criteria from its board candidate selection process. Both proposals target how the board is organized and how directors are chosen over the long term.

Colgate-Palmolive’s board has recommended that shareholders vote against both measures. The company’s stance signals support for its current leadership structure and existing director selection framework at a time when many large-cap firms are debating similar governance topics.

The upcoming votes arrive as investors can see different return profiles depending on their holding period in Colgate-Palmolive shares. Over the past three and five years, the stock has delivered double-digit gains, but the last year shows a modest decline despite a positive year-to-date performance.

For shareholders, the proposals are framed as being less about near-term earnings and more about how power, oversight, and board skills are balanced in the years ahead. The outcome could influence future board composition and policies on independence and DEI, factors some investors weigh alongside traditional financial metrics.

Observers are watching support levels for each proposal, particularly from large institutional holders, as a gauge of governance expectations for Colgate-Palmolive relative to peers. Any board or management commentary after the meeting, as well as how these governance discussions align with the company’s growth-focused strategy across oral care, personal care, home care, and pet nutrition, are seen as key elements to monitor.